Skip to content
Blood clots are commonly missed. According to the National Blood Clot Alliance (NBCA), “fewer than 1 in 4 people have any recognition of blood […]
A new class of medicines provides hope for patients at risk of dangerous blood clots Read More »
Patients’ stories are powerful—especially when it comes to advocacy, agreed panelists at the Biotechnology Innovation Organization (BIO) Patient and Health Advocacy Summit. An October
Patients are your best advocates – here’s how to support them Read More »
Sepsis is the third most common cause of disease-related death in the United States. Bacterial infections are the most common cause of sepsis. But
How COVID-19 is increasing incidence of another life-threatening condition Read More »
“We have 87 million patients in America who rely on Medicaid for either supplemental or primary coverage,” began Virginia McMillin of Jazz Pharmaceuticals during
How to protect patient access to Medicaid Read More »
“Patient advocacy is at heart of what BIO is working to accomplish within this community to extend the lives of patients,” said Rachel King,
Why patient advocacy is ‘at the heart’ of biotech sector’s work Read More »
“The Inflation Reduction Act (IRA) was one of President Biden’s signature achievements and will help many Americans,” began Christina Hochul of Alexion Pharmaceuticals, Inc.,
Inflation Reduction Act: Unintended consequences for rare disease, orphan drugs Read More »
The Biotechnology Innovation Organization (BIO) Patient and Health Advocacy Summit is kicking off in Washington, D.C. Now in its 12th year, the event brings
What we’re watching at the 2023 Patient & Health Advocacy Summit Read More »
Federal Trade Commission (FTC) proposals for new rules to permit more aggressive opposition to mergers would interfere with the economic ecosystem that is essential
FTC plans for aggressive merger enforcement threaten biotech innovation, BIO says Read More »
The 2023 Biotechnology Innovation Organization (BIO) Investor Forum ended the way it began: with caution about the months ahead and hope companies will continue
The market outlook for life science – and how biotechs can weather the storm Read More »
One Saturday in 2019, Mike Lavorel went out with some friends and ordered some oysters. By Monday, he was ill and by Tuesday, he
‘Miracle Man’ beat sepsis, but now needs a kidney Read More »
